Blueprint
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of October 2018.
Commission
File Number: 000-53805
Intellipharmaceutics International Inc.
(Translation
of registrant's name into English)
30 WORCESTER ROAD TORONTO, ONTARIO M9W 5X2
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F. Form 20-F [ x ]
Form 40-F [
]
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1): ___
Note: Regulation S-T Rule 101(b)(1) only permits the
submission in paper of a Form 6-K if submitted solely to provide an
attached annual report to security holders.
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ___
Note: Regulation S-T Rule 101(b)(7) only permits the
submission in paper of a Form 6-K if submitted to furnish a report
or other document that the registrant foreign private issuer must
furnish and make public under the laws of the jurisdiction in which
the registrant is incorporated, domiciled or legally organized (the
registrant's “home
country”), or under the
rules of the home country exchange on which the registrant's
securities are traded, as long as the report or other document is
not a press release, is not required to be and has not been
distributed to the registrant's security holders, and, if
discussing a material event, has already been the subject of a Form
6-K submission or other Commission filing on EDGAR.
This
Report of Foreign Private Issuer on Form 6-K and the attached
exhibit 99.1 shall be incorporated by reference into the Company's
effective Registration Statements on Form F-3, as amended and
supplemented (Registration Statement Nos. 333-172796 and
333-218297), filed with the Securities and Exchange Commission,
from the date on which this Report is filed, to the extent not
superseded by documents or reports subsequently filed or furnished
by Intellipharmaceutics International Inc. under the Securities Act
of 1933 or the Securities Exchange Act of 1934.
Preliminary Results for the Quarter Ended August 31,
2018
Although the
financial statements of Intellipharmaceutics International Inc.
(the “Company”) as of and for the quarter ended August
31, 2018 are not yet available, the following information reflects
the Company’s estimates of its results based on currently
available information.
For the
Quarter Ended August 31, 2018, the Company expects to report the
following results:
(in
thousands, except for per share amounts)
|
Balance
Sheet Data
|
|
|
|
|
|
Cash and cash
equivalents
|
$57
|
|
Total
assets
|
$5,634
|
|
Total
liabilities
|
$10,593
|
|
Net
equity
|
$(4,959)
|
|
|
|
|
Statement
of Operations
|
|
|
|
Three month
period
|
|
Revenue
|
$414
|
|
Net
loss
|
$(3,954)
|
|
Net loss per share
– basic and diluted
|
$(0.91)
|
Revenues represent
quarterly profit share payments from the Company’s commercial
partners. Operating expenses, consisting primarily of research and
development and general and administrative expenses, were
significantly higher in the third quarter due to clinical studies
related to Oxycodone ER as well as higher patent litigation
expenses.
The
foregoing constitute forward-looking statements within the meaning
of the United States Private Securities Litigation Reform Act of
1995 and/or "forward-looking information" under the Securities Act
(Ontario). Risks
and uncertainties relating to the Company and its business can be
found in the "Risk Factors" section of the Company's latest annual
information form, latest Form 20-F, and latest Form F-1, including
amendments thereto (including any documents forming a part thereof
or incorporated by reference therein), as well as in the
Company’s reports, public disclosure documents and other
filings with the securities commissions and other regulatory bodies
in Canada and the U.S., which are available on www.sedar.com and www.sec.gov. These preliminary results
are unaudited and represent the Company’s estimates only, and
the Company’s actual results could differ materially from
those set forth above as a result of various factors, including
those listed under such “Risk Factors”. In addition,
these factors include, without limitation, the risk that additional
information may arise during the Company's close process or as a
result of subsequent events that would require the Company to make
adjustments to the financial information, as well as the risk that
adjustments to the Company’s financial statements may be
identified through the course of the Company’s independent
registered public accounting firm completing its review of the
Company's financial statements.
Intellipharmaceutics Announces Completion of the Clinical Component
of Category 2 and 3 Human Abuse Liability Studies for Oxycodone
ER
The
Company announced today that it has completed the clinical part of
its Category 2 and 3 human abuse liability studies for its
Oxycodone ER (oxycodone hydrochloride extended-release formulation)
product candidate to support its abuse-deterrent label claims for
both the oral and intranasal route of administration. A copy of the
press release is attached as Exhibit 99.1 to this report and is
incorporated herein by reference.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
|
Intellipharmaceutics International Inc.
(Registrant)
/s/ Andrew
Patient
|
|
Date:
October 10, 2018
|
Andrew
Patient
Chief Financial Officer
|
|
Exhibit
|
Description
|
|
99.1
|
News
Release dated October [10], 2018 – Intellipharmaceutics
Announces Completion of the Clinical Component of Category 2 and 3
Human Abuse Liability Studies for Oxycodone ER
|